Whole group (n=256) | Stent group (n=124) | No further treatment group (n=132) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dissection | p Value | Dissection | p Value | Dissection | |||||||||
None/type A-B (group B) (n=111) | Type C (group A) n=45) | None/type A-B (group B) (n=111) | Type C (group A) (n=13) | None/type A-B (group B) (n=100) | Type C (group A) (n=32) | p Value | |||||||
MACE (30 days) | 5 (5%) | 3 (7%) | NS | 2 (2%) | 2 (15%) | 0.054 | 3 (2%) | 1 (3%) | NS | ||||
MACE (12 month) | 23 (11%) | 10 (22%) | 0.041 | 7 (6%) | 4 (31%) | 0.002 | 16 (16%) | 6 (19%) | NS | ||||
TLR (12 month) | 14 (7%) | 8 (17%) | 0.016 | 3 (3%) | 4 (31%) | < 0.001 | 11 (11%) | 4 (13%) | NS |
Values are n (%).
MACE, major adverse cardiac events; TLR, target lesion revascularisation.